
    
      This trial is a prospective, multi-center, and exploratory clinical study, taking the Cancer
      Hospital of Jiangxi province as the lead unit, combined with breast cancer diagnosis and
      treatment norms, multi-center collaborative research to explore the iDFS of radiotherapy
      combined with carilizumab for triple-negative breast cancer of different subtypes and provide
      optimal personalized treatment options.
    
  